{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.1.', 'Efficacy Assessments', '52', '8.1.1.', 'Hospitalization', '52', '8.1.2.', 'Clinical Deterioration', '52', '8.1.3.', 'Myasthenia Gravis Activities of Daily Living Profile', '54', '8.1.4.', 'Quantitative Myasthenia Gravis Score', '54', '8.1.5.', 'Myasthenia Gravis Composite Score', '54', '8.1.6.', 'Euro Quality of Life 5D-5L', '54', '8.1.7.', 'Revised Myasthenia Gravis Qualify of Life-15 Scale', '54', '8.1.8.', 'Neurological Quality of Life Fatigue', '55', '8.1.9.', 'Myasthenia Gravis Foundation of America Clinical Classification', '55', '8.1.10.', 'Myasthenia Gravis Foundation of America Post-Intervention Status', '55', '8.2.', 'Safety Assessments', '55', '8.2.1.', 'Physical Examination', '55', '8.2.2.', 'Vital Signs and Pulse Oximetry', '55', '8.2.3.', 'Electrocardiogram', '55', '8.2.4.', 'Clinical Safety Laboratory Assessments', '56', '8.2.4.1.', 'Urinalysis and Urine Chemistry', '56', '8.2.4.2.', 'Virus Serology', '56', '8.2.4.3.', 'Immunogenicity Assessments', '56', '8.2.5.', 'Suicidal Risk Monitoring', '56', '8.2.5.1.', 'Columbia-Suicidal Severity Rating Scale', '56', '8.3.', 'Adverse Events and Serious Adverse Events', '57', '8.3.1.', 'Time Period and Frequency for Collecting Adverse Event and Serious', 'Adverse Event Information', '57', '8.3.2.', 'Method of Detecting Adverse Events and Serious Adverse Events', '57', '8.3.3.', 'Follow-up of Adverse Events and Serious Adverse Events', '57', '8.3.4.', 'Regulatory Reporting Requirements for Serious Adverse Events', '58', '8.3.5.', 'Pregnancy', '58', '8.3.6.', 'Vaccine and Antibiotic Prophylaxis', '58', '8.3.7.', 'Study Drug Administration Reactions', '59', '8.3.7.1.', 'Local and Systemic Reactions', '59', '8.3.7.2.', 'Infusion-Associated Reactions', '59', '8.4.', 'Adverse Events of Special Interest', '59', 'Page 10 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.5.', 'Pharmacokinetics', '59', '8.6.', 'Pharmacodynamics', '60', '8.7.', 'Genetics', '60', '8.8.', 'Biomarkers', '60', '8.9.', 'Healthcare Resource Utilization', '60', '9.', 'STATISTICAL CONSIDERATIONS', '61', '9.1.', 'Statistical Hypotheses', '61', '9.1.1.', 'Primary Hypothesis', '61', '9.1.2.', 'Secondary Hypotheses', '61', '9.1.3.', 'Hypotheses Related to Exploratory Efficacy Objectives', '62', '9.1.4.', 'Estimation of Treatment Effect for Secondary and Exploratory Hypotheses', '62', '9.2.', 'Sample Size Determination', '63', '9.3.', 'Populations for Analyses', '63', '9.4.', 'Statistical Analyses', '63', '9.4.1.', 'Enrollment and Disposition', '63', '9.4.2.', 'Demographics, Baseline Characteristics, Inclusion and Exclusion Criteria,', 'and Protocol Deviations', '64', '9.4.3.', 'Medical/Surgical History, Physical Examination, and Myasthenia Gravis', 'History', '64', '9.4.4.', 'Prior and Concomitant Medications', '64', '9.4.5.', 'Efficacy Analyses', '64', '9.4.5.1.', 'Primary Efficacy Analysis', '64', '9.4.5.2.', 'Sensitivity Analyses for Primary Endpoint', '65', '9.4.5.3.', 'Analyses of Secondary and Exploratory Endpoints', '65', '9.4.5.4.', 'Multiplicity Adjustment for Primary and Secondary Endpoints', '65', '9.4.5.5.', 'Per Protocol Analyses for Primary and Secondary Endpoints', '66', '9.4.6.', 'Safety Analyses', '66', '9.4.6.1.', 'Analysis of Adverse Events', '66', '9.4.6.2.', 'Analysis of Clinical Laboratory Parameters, Vital Sign Measurements and', 'Electrocardiogram Parameters', '66', '9.4.6.3.', 'Other Safety Analyses', '66', '9.4.6.4.', 'Analysis of Pharmacokinetics and Pharmacodynamics', '66', '9.4.6.5.', 'Analysis of Immunogenicity', '67', 'Page 11 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}